A detailed history of Parallel Advisors, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,377 shares of RNA stock, worth $59,555. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,377
Previous 46 2893.48%
Holding current value
$59,555
Previous $1,000 6200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$37.21 - $48.14 $49,526 - $64,074
1,331 Added 2893.48%
1,377 $63,000
Q2 2024

Aug 08, 2024

BUY
$22.73 - $40.85 $659 - $1,184
29 Added 170.59%
46 $1,000
Q4 2023

Feb 09, 2024

SELL
$4.87 - $9.37 $1,485 - $2,857
-305 Reduced 94.72%
17 $0
Q3 2023

May 20, 2024

BUY
$6.3 - $11.35 $1,455 - $2,621
231 Added 253.85%
322 $2,000
Q3 2023

Nov 13, 2023

BUY
$6.3 - $11.35 $2,028 - $3,654
322 New
322 $2,000
Q1 2023

May 20, 2024

BUY
$15.35 - $25.65 $1,135 - $1,898
74 Added 435.29%
91 $1,000
Q1 2023

Apr 25, 2023

BUY
$15.35 - $25.65 $1,074 - $1,795
70 Added 333.33%
91 $1,000
Q4 2022

Feb 03, 2023

SELL
$10.06 - $22.66 $60 - $135
-6 Reduced 22.22%
21 $0
Q3 2022

Nov 10, 2022

BUY
$15.46 - $23.43 $92 - $140
6 Added 28.57%
27 $0
Q2 2022

Aug 01, 2022

BUY
$11.18 - $20.5 $234 - $430
21 New
21 $0
Q1 2022

Apr 28, 2022

SELL
$14.2 - $23.78 $2,428 - $4,066
-171 Closed
0 $0
Q4 2021

Jan 20, 2022

BUY
$20.4 - $28.66 $3,284 - $4,614
161 Added 1610.0%
171 $4,000
Q1 2021

Apr 23, 2021

BUY
$20.28 - $28.15 $202 - $281
10 New
10 $0

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.25B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.